Some users report transient fatigue, mild headaches, dizziness, sleep changes, or water retention, particularly during the first 1-2 weeks
Oral administration of US FDA approved DPP-4 inhibitors, such as Saxagliptin, Vildagliptin, Anagliptin, etc., prolongs the half-lives and thus the action of GLP-1 and GIP, which in turn improves glycemic control with minimal risk of hypoglycemia (Havale and Pal, 2009)
100 200 2 4
Kessler RC, Green JG, Gruber MJ, Sampson NA, Bromet E, Cuitan M, et al
For example, Eli Lilly has just reported clinical trial results showing the benefits of its GLP-1, Zepbound (tirzepatide), in reducing the occurrence of sleep apnea events among people with obesity or overweight
P., Hayoun, Y